PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing… Read More..

SANTA BARBARA, CA / ACCESSWIRE / March 5, 2024 / DRYWORLD Brands Inc. (OTC PINK:IBGR), a premium performance sports brand, today shared a corporate update highlighting its growth in 2023 and the company's outlook for 2024. Notably, the company notched 1,700% growth in Q1 2024 sales as compared to the… Read More..

KELOWNA, BC / ACCESSWIRE / March 4, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, informs that its wholly-owned and patented DehydraTECH-CBD formulation, when administered to rodents in an 8-week study (DIAB-A22-1), resulted in weight loss of 7% and a reduction… Read More..